Sana Biotechnology has closed its first round with more than $700m after investors including GV swung behind its vision to commercialise cell therapies.
Sana Biotechnology, a US-based developer of stem cell medicines based on research at multiple universities, closed its inaugural funding round at $700m on Tuesday with commitments from investors including conglomerate Alphabet.
F-Prime Capital, a unit of financial services group Fidelity, also took part in the round, as did Arch Venture Partners, Flagship Pioneering, Canada Pension Plan Investment Board, Baillie Gifford, Alaska Permanent Fund and the Public Sector Pension Investment Board.
Bezos Expeditions, Omega Funds, Altitude Life Science Ventures and several undisclosed institutional investors filled out the investor line-up. Alphabet took part through early-stage corporate venturing subsidiary GV.
The round was raised over multiple tranches, with F-Prime Capital, Arch Venture Partners and Flagship Pioneering having already been revealed as investors at Sana’s launch in January 2019.
Sana Biotechnology is working on technology to repair and control genes in cells and to replace missing or damaged cells to tackle…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
